ArticleFrontiers in cellular and infection microbiology2025
The impact of rifampin on the efficacy of implant retention and prosthesis removal in staphylococcal periprosthetic joint infection.
Article in Frontiers in cellular and infection microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Rifampicin in Osteoarticular Infections: A Comprehensive Review of Current Evidence.Antibiotics (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: The purpose of this study was to evaluate the impact of adjunctive rifampicin therapy on the outcomes of prosthesis retention versus removal in patients with staphylococcal prosthetic joint infection (PJI) undergoing antibacterial treatment. Methods: A retrospective study was conducted on 227 patients diagnosed with Staphylococcal PJI from March 2014 to September 2023 who underwent debridement, antibiotics, and implant retention (DAIR) or explantation and revision surgery. Based on antimicrobial susceptibility testing, we used an effective baseline antibiotic regimen. We defined the combination of this regimen with rifampicin as the "rifampicin treatment group" and the regimen without rifampicin as the "non-rifampicin treatment group". Results: A total of 79 patients were included in the rifampin treatment group and 148 in the non-rifampin treatment group. There was no significant difference in the remission rate of PJI between the rifampin treatment group and the non-rifampin treatment group (79.75% vs 73.65%, p = 0.083). Additionally, Kaplan-Meier survival curve analysis showed no statistically significant difference between the two groups (p = 0.509). However, the incidence of drug-related adverse events was significantly higher in the rifampin treatment group compared to the non-rifampin treatment group (31.65% vs 8.78%, p < 0.001). There were no significant difference in treatment success rates between the use and non-use of rifampin in DAIR, one-stage revision, or two-stage revision, as well as in hip or knee joints. Binary logistic regression analysis identified diabetes and active smoking as independent significant risk factors for treatment failure, while rifampin was not an independent risk factor affecting the outcome. Conclusion: The study has not demonstrated that the standard antibiotic regimen combined with rifampin has a significant effect on the efficacy of retaining or removing prostheses in staphylococcal PJI, but rather increases drug-related adverse events. Standard surgical procedures, accurate pathogen diagnosis, and treatment are particularly crucial in the management of PJI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.